Gilead Sciences Inc GILD

Morningstar Rating
$170.10 +2.47 (1.47%)
View Full Chart

Company Report

Price vs Fair Value

GILD is trading at a LOCK|v&j^@^m premium.
Price
$167.58
Fair Value
Mq>
Uncertainty
LOCK|b$gs
1-Star Price
LOCK|!.H
5-Star Price
LOCK|#.&
Economic Moat
LOCK|Xd
Capital Allocation
LOCK|Mc$s^q

Bulls Say, Bears Say

Bulls

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Bears

Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.

News

Articles & Videos

Trading Information

Previous Close Price
$167.58
Day Range
$165.69–171.37
52-Week Range
$116.88–176.58
Bid/Ask
$170.03 / $170.09
Shares Outstanding
1.24B
Market Cap
$210.10B
Volume/Avg
3M / 6M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
6.75
Dividend Yield (Trailing)
1.94%
Dividend Yield (Forward)
1.96%
Dividend Payment Schedule
Mar, Jun, Sep, Dec
Total Yield
2.46%

Company Profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
17,000

Competitors

Valuation

Metric
GILD
ABBV
MRK
Price/Earnings (Normalized)
—33.44109.77
Price/Book Value
16.00—8.12
Price/Sales
6.757.925.43
Price/Cash Flow
14.1922.2516.52
Price/Earnings
GILD
ABBV
MRK

Financial Strength

Metric
GILD
ABBV
MRK
Quick Ratio
0.950.560.78
Current Ratio
1.380.871.35
Interest Coverage
−1.785.203.33
Quick Ratio
GILD
ABBV
MRK

Profitability

Metric
GILD
ABBV
MRK
Return on Assets (Normalized)
−0.60%16.61%2.53%
Return on Equity (Normalized)
−1.77%—7.02%
Return on Invested Capital (Normalized)
0.51%36.97%4.79%
Return on Assets
GILD
ABBV
MRK

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|FT@f<QSpLOCK|@lr$1T
Johnson & Johnson
JNJ
LOCK|B^rSHJ>LOCK|h@$680B
AbbVie Inc
ABBV
LOCK|#Q!k#XLOCK|JtV$521B
Roche Holding AG ADR
RHHBY
LOCK|DxZyHY$LOCK|#>n$389B
Merck & Co Inc
MRK
LOCK|sWm^GBNLOCK|&>F$356B
Novartis AG ADR
NVS
LOCK|<$C?xpLcLOCK|s^$306B
AstraZeneca PLC
AZN
LOCK|<>NxdTCLOCK|V^$288B
Amgen Inc
AMGN
LOCK|D<%SkzdpLOCK|?Dl$250B
Novo Nordisk AS ADR
NVO
LOCK|?b%vgGPLOCK|rd$185B

Sponsor Center